Generic substitution: additional challenge for adherence in hypertensive patients?

References

• Andersson K, Bergström G, Petzold MG, et al. Impact of a generic substitution reform on patients’ and society's expenditure for pharmaceuticals. Health Policy 2007;81:376-84
   PubMed Web of Science ®Google Scholar
• Gumbs PD, Verschuren WMM, Souverein PC, et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol 2007;64:680-5
   PubMed Web of Science ®Google Scholar
• Håkonsen H, Horn AM, Toverud EL. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994–2004?. Health Policy 2009;90:277-85
   PubMed Web of Science ®Google Scholar
• Morgan SG, Agnew JD, Barer ML. Seniors’ prescription drug cost inflation and cost containment: evidence from British Columbia. Health Policy 2004;68:299-307
   PubMed Web of Science ®Google Scholar
• The Norwegian Association of Pharmaceutical Manufacturers. Facts and Figures 2009. http://www.legemiddelstatistikk.com/tf/2009/index.html [Accessed 28.04.2009]
   Google Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO, 2003
   Google Scholar
• Morris LS, Schulz RM. Patient compliance - an overview. J Clin Pharm Ther 1992;17:283-95
   PubMed Web of Science ®Google Scholar
• Burnier M, Santschi V, Favrat B, et al. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl 2003;21:S37-42
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, et al, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206
   PubMed Web of Science ®Google Scholar
• Barrett JS, Batra V, Chow A, et al. PhRMA perspective on population and individual bioequivalence. J Clin Pharmacol 2000;40:561-70
   PubMed Web of Science ®Google Scholar
• Nakai K, Fujita M, Ogata H. International harmonization of bioequivalence studies and issues shared in common. Yakugaku Zasshi 2000;120:1193-200
   PubMed Web of Science ®Google Scholar
• Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc 2000;40:378-83
   Google Scholar
• Himmel W, Simmenroth-Nayda A, Niebling W, et al. What do primary care patients think about generic drugs?. Int J Clin Pharmacol Ther 2005;43:472-9
   PubMed Web of Science ®Google Scholar
• Kjoenniksen I, Lindbaek M, Granas AG. Patients’ attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006;28:284-9
   PubMed Web of Science ®Google Scholar
• Andersen MLE, Laursen K, Schaumann M, et al. How do patients evaluate the newly introduced system of substituting prescriptions?. Ugeskrift for læger 2000;162:6066-9 [in Danish]
   PubMedGoogle Scholar
• Thiebaud P, Patel BV, Nichol MB, et al. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005;11:670-4
   PubMed Web of Science ®Google Scholar
• van Wijk BLG, Klungel OH, Heerdink ER, et al. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens 2004;22:1831-7
   PubMed Web of Science ®Google Scholar
• van Wijk BLG, Klungel OH, Heerdink ER, et al. Generic substitution of antihypertensive drugs: does it affect adherence?. Ann Pharmacother 2006;40:15-20
   PubMed Web of Science ®Google Scholar
• Buurma H, Bouvy ML, De Smet PA, et al. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 2008;33:17-23
   PubMed Web of Science ®Google Scholar
• Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the necessity-concerns framework. J Psychosom Res 2008;64:41-6
   PubMed Web of Science ®Google Scholar
• Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357-62
   PubMed Web of Science ®Google Scholar
• Grégoire JP, Moisan J, Guibert R, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol 2002;55:728-35
   PubMed Web of Science ®Google Scholar
• Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med 2001;16:793-9
   PubMed Web of Science ®Google Scholar
• Lundberg L, Johannesson M, Isacson DGL, et al. Effects of user charges on the use of prescription medicines in different socio-economic groups. Health Policy 1998;44:123-34
   PubMed Web of Science ®Google Scholar
• Elliott RA, Shinogle JA, Peele P, et al. Understanding medication compliance and persistence from an economics perspective. Value Health 2008;11:600-10
   PubMed Web of Science ®Google Scholar
• Garber MC, Nau DP, Erickson SR, et al. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 2004;42:649-52
   PubMed Web of Science ®Google Scholar
• Wang PS, Benner JS, Glynn RJ, et al. How well do patients report noncompliance with antihypertensive medications? a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 2004;13:11-19
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-26
   PubMed Web of Science ®Google Scholar